This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NFATC2 · Western blot design guide
NFATC2 Western Blot Planning Guide
Plan a NFATC2 Western blot around the catalog-observed 100.1 kDa band, image-backed A00969 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
NFATC2 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 100.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Bone marrow | |
| Negative control | Heart muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 100.1 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated NFATC2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Bone marrow |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00969 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected NFATC2 Western Blot Band Size?
Use the product-observed 100.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 100.1 kDa | Matches the authoritative product WB observation. |
| 100.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected NFATC2 appearancePlan around 100.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 100.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 100.1 kDa from UniProt Q13469; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00969. |
| Situation | Likely cause | Next action |
|---|---|---|
| 100.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing NFATC2 band
A00969 · NFATC2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NFATC2 Western blot
🧪Use Bone marrow as the first positive-control candidate and Heart muscle as the HPA Not detected negative candidate.
Positive control: Bone marrow (High)
Negative control: Heart muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for NFATC2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
| Lymph node | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced NFATC2 Western Blot Tips
Deeper troubleshooting and optimisation questions for NFATC2, answered from its protein features.
Which band should guide the blot?
Use 100.1 kDa, the observation attached to the authoritative A00969 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 100.1 kDa expectation.
Which positive control should I start with?
Start with Bone marrow, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Heart muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for NFATC2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00969 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
NFATC2 Western Blot Reagents
Human-reactive NFATC2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-NFAT1/NFATC2 Antibody Picoband®
Cat # A00969
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q13469
- Human Protein Atlas — NFATC2
- A00969 product record
- PMC6199214 — NFATC2 is a novel therapeutic target for colorectal cancer stem cells (OncoTargets and therapy, 2018)
- PMC5543739 — Interaction between NFATc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t (BMC molecular biology, 2017)
- PMC2211785 — Nuclear factor of activated T cells balances angiogenesis activation and inhibition (The Journal of experimental medicine, 2004)
